GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)

Cancer Chemother Pharmacol. 2014 Nov;74(5):883-98. doi: 10.1007/s00280-014-2547-0. Epub 2014 Sep 6.


Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. Correct diagnosis with thorough use of pathologic and molecular tools of GIST mutations has been of the foremost importance. GIST are usually (95 %) KIT positive and harbor frequent KIT or platelet-derived growth factor receptor α-activating mutations. This deep molecular understanding has allowed the correct classification into risk groups with implications regarding prognosis, essential use in the development of targeted therapies and even response prediction to this drugs. Treatment has been evolving and an update to include lessons learned from recent trials in advanced disease as well as controversies in the adjuvant setting that are changing daily practice, is reviewed here. An effort from the Spanish Group for Sarcoma Research with investigators from the group has been undertaken to launch this third version of the GIST guidelines and provide a practical means for the different disciplines that treat this complex disease.

Publication types

  • Review

MeSH terms

  • Disease-Free Survival
  • Gastrointestinal Neoplasms / diagnosis*
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / genetics
  • Gastrointestinal Stromal Tumors / diagnosis*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / genetics
  • Humans
  • Mutation
  • Practice Guidelines as Topic*
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Sarcoma / diagnosis*
  • Sarcoma / drug therapy
  • Sarcoma / genetics


  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-kit
  • Receptor, Platelet-Derived Growth Factor alpha